EASL is launching a new educational initiative called EASL Molecular Tumour Boards (EASL-MTB) aiming at discussing clinical cases of hepatocellular carcinoma (HCC), hepatocellular adenoma (HCA) and cholangiocarcinoma (CCA) with Target Enrichment Sequencing (TES) results and allocation of treatment. The main purpose of this activity is to educate physicians and health allies on precision oncology based on molecular data in primary liver malignancies.
Format
The format will be a 45-min live webinar, including 10 minutes of Q&A where the audience will be able to address questions. The webinar will be available afterwards on-demand on EASL Campus with a chat function for continued discussions.
Learning objectives
- Learn about the management and treatment of intrahepatic cholangiocarcinoma
- Understand what precision oncology is based on molecular data (i.e. Target Enrichment Sequencing or TES)
Targeted audience
- Hepatologists
- Oncologists
- Radiologists
- Pathologists
- Physicians
- Scientists
Faculty
- Hepatologist (Chair): Arndt Vogel, Germany
- Case presenter: Anna Saborowski, Germany
- Pathologist: Julien Calderaro, France
- Radiologist: Irene Bargellini, Italy
- Molecular biologist: Daniela Sia, USA
- Oncologist: Angela Lamarca, Spain
Programme
- Introduction, objectives, and road map of treatment allocation with systemic therapies (5 min)
- Presentation of the case (5 min)
- Discussion pathology (3 min)
- Discussion radiology (3 min)
- Discussion molecular biology (3 min)
- Discussion oncology (3 min)
- Open discussion (15 min)
- Q&A (10 min)